These engineered molecules can simultaneously bind two distinct antigens, typically one expressed on tumor cells, e.g., Prostate-Specific Membrane Antigen (PSMA), and another on immune effector cells, such as CD3 or CD28 on T cells, thereby promoting an immunological synapse that enables targeted immune activation [55,56]. Here, FOLH1 is linked to neoplasm.